Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $175.00 short call and a strike $185.00 long call offers a potential 18.91% return on risk over the next 35 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $175.00 by expiration. The full premium credit of $1.59 would be kept by the premium seller. The risk of $8.41 would be incurred if the stock rose above the $185.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 24.63 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks
Thu, 16 May 2019 09:00:00 +0000
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
Amgen Showcases Oncology Pipeline At ASCO 2019
Wed, 15 May 2019 21:07:00 +0000
THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ — Amgen (AMGN) today announced that data from its oncology pipeline will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Seven investigational assets will be featured across a range of hematologic malignancies and solid tumors. “Biology and human genetics have been the foundation of Amgen's innovation for the last four decades,” said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
Insulet and West Pharma Proven Winners in Growing Wearable Devices Market
Wed, 15 May 2019 16:28:17 +0000
With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.
3 Stocks With Big News Coming at ASCO 2019
Wed, 15 May 2019 14:16:00 +0000
These cancer drug developers could report market-moving news soon.
The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi
Wed, 15 May 2019 11:50:08 +0000
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc …
Also on Market Tamer…
Follow Us on Facebook